Drugs / Biejia-Ruangan
Biejia-Ruangan
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT01965418 Comparator | Sep 2013 → Dec 2015 | chronic hepatitis B virus infection, fibrotic liver disease | Beijing 302 Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Biejia-Ruangan | “Biejia-Ruangan (BR) has been approved in China as an antifibrotic traditional Chinese medicine drug in patients with chronic liver diseases.” PMID 32437567 ↗ Mar 2022 |
| Known as | Fufang Biejia Ruangan Tablet | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01965418 ↗ |
| Known as | RGT | “the compound biejia ruangan (RGT) administered for fibrosis” PMID 25381721 ↗ Nov 2014 |
| Modality | Traditional medicine (herbal / TCM) | “Biejia-Ruangan (BR) has been approved in China as an antifibrotic traditional Chinese medicine drug in patients with chronic liver diseases.” PMID 32437567 ↗ Mar 2022 |